It’s been a busy spring for drug development. We’ve had leadership changes at FDA, legislative pushes in Congress, and a host of conferences and meetings to present and advance ideas from the cutting edge of science and policy. It’s a lot of keep up with. Here are the biggest stories from the last few months.
|
|
|
|
|
|
On April 28th, the House Energy and Commerce Committee (E&C) released the second discussion draft of the 21st Century Cures bill. On April 30th, the committee held a hearing to discuss new provisions in the legislation, including an increase in NIH appropriations. Two weeks later, a new version of the bill was released, in which additional updates were made. The next day, on May 14th, the E&C Subcommittee on Health advanced the legislation to the full committee by a voice vote. Finally, on May 21st, the full Energy and Commerce Committee unanimously approved the 21st Century Cures Act, H.R. 6.
|
|
|
The Senate HELP Committee has embarked on a parallel initiative to 21st Century Cures, called “Continuing America’s Leadership.” The committee has convened three hearings to date, on precision medicine, biomarkers and translational research, and on the role of FDA and NIH in fostering biomedical innovation.
|
|
|
|
|
|
|